Breast Cancer
Immunotherapy Plus Chemo Improves Metastatic TNBC Outcomes
BY GINA COLUMBUS
More Immunotherapy May Enter TNBC Space
BY JESSICA HERGERT
Unmet Needs Remain in TNBC Treatment
BY KRISTI ROSA
Ovarian Suppression Plus AI Treatment Can Have Major Adverse Events
BY DAWN L. HERSHMAN, MD, MS
Radiation's Role Shifts in Breast Cancer
BY JESSICA HERGERT
The HER2+ Breast Cancer Landscape Continues to Change
BY ELLIE LEICK
Nurses: Frequently Discuss AEs With Your Patients
BY MADELINE KUIPER, MSN, RN, OCN
Monitor Toxicities When Treating Breast Cancer With Immunotherapy
BY LEISHA A. EMENS, MD, PHD
FDA Accepts BLA for Eflapegrastim for Chemo-Induced Neutropenia
BY GINA COLUMBUS
External Resources
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.